Pharmaceuticals News

New real-world results for Vabysmo in nAMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals1-3Advanced AI-enabled...

Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life ZUG, Switzerland, October 1, 2026 --...

REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other...

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus1By...

Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée

- La publicación en esta prestigiosa revista, tras un riguroso proceso de revisión por parte de otros expertos del sector, avala el estudio VIRAGE y respalda la evaluación continuada de VCN-01 en el...

东京, Oct. 01, 2026 (GLOBE NEWSWIRE) -- 日本 Omotesando Helene Clinic与韩国 Maison Privé Clinic 已签署合作备忘录（MOU），旨在促进两国之间的医疗交流，并进一步完善海外患者的就医支持体系。 根据本次协议，双方将在多个领域展开合作，包括再生医疗等医疗领域的信息交流、医疗人员交流、患者就诊前后的支持，以及 VVIP...

GLEN ALLEN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new...

Oculis Announces Resignation of Lionel Carnot from Board of Directors ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global...